Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial.
about
Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's diseasePredicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel diseaseHow should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?Disease monitoring in inflammatory bowel diseaseUse of thiopurines in inflammatory bowel diseaseHepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel diseaseEvaluation of inflammatory activity in Crohn's disease and ulcerative colitisUse of the tumor necrosis factor-blockers for Crohn's diseaseBiomarkers as potential treatment targets in inflammatory bowel disease: A systematic reviewSystematic review with meta-analysis: infliximab and immunosuppressant therapy vs. infliximab alone for active ulcerative colitisEvolving Concepts in Phases I and II Drug Development for Crohn's Disease.Biological treatment of Crohn's disease.New Data on the Use of Biologic Agents for Crohn's Disease and Ulcerative Colitis: Highlights from the 2009 CCFA Advances in IBD MeetingUse of thiopurines in inflammatory bowel disease: Safety issues.Combination therapy for inflammatory bowel diseaseDiagnosis and management of intestinal Behçet's disease.Management of Crohn's disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease.Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease.Lifestyle-related disease in Crohn's disease: relapse prevention by a semi-vegetarian diet.Emerging data in the concomitant use of immunomodulators and biologic therapies.Adverse events in IBD: to stop or continue immune suppressant and biologic treatmentUpdate on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease.The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?Current status of thiopurine analogues in the treatment in Crohn's disease.Practical medical management of Crohn's disease.Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases.A systematic review of measurement of endoscopic disease activity and mucosal healing in Crohn's disease: recommendations for clinical trial design.Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: a systematic review and meta-analysis.Infliximab to treat Crohn's disease: an update.Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseasesOptimizing the use of anti-tumor necrosis factor in the management of patients with Crohn's disease.Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis.Effectiveness and risk associated with infliximab alone and in combination with immunosuppressors for Crohn's disease: a systematic review and meta-analysisEffectiveness and Safety of Immunomodulators With Anti-Tumor Necrosis Factor Therapy in Crohn's DiseaseWhen should combination therapy for patients with Crohn's disease be discontinued?Mucosal healing in inflammatory bowel disease: Maintain or de-escalate therapy.Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease.Are we giving biologics too late? The case for early versus late use.Loss of response to long-term infliximab therapy in children with Crohn's disease.Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies.
P2860
Q24186291-FE6F1B45-9131-4DA2-A95B-9772E9FA381CQ26745721-4D33016B-B0A5-4D76-BE4F-D18151B3F95AQ26777409-DEDEF4AD-BE28-4169-BF35-C2500ECFC73FQ26777553-61A751DC-21F7-4E34-A0D9-662843970289Q26824662-09F9088E-082C-4EF3-AB10-597A67875998Q26827444-552A60DD-DDB3-412B-BE1C-CF6E234D9042Q26996550-F8918479-76DE-498C-B5D0-22B1E8E76993Q27030762-9BD88D2B-C615-42F5-AE07-35E0417AAD99Q28087434-3A472107-F134-42B7-A558-3332FF2FF13DQ28088683-832163D0-9B1C-4478-A717-2ACDAF8C079DQ30248641-4E4AF981-C4AC-4298-9419-DE5C7DFEA745Q33354991-3E951260-3205-4A91-BA86-381B9695CF8BQ33612263-0F4EB089-FEA2-487F-A84D-8CF6D09EBB92Q33621267-36102921-D574-4F9A-85D0-026272ADB7ABQ33646452-3553E651-AA9D-4513-B5D7-15FB53DF6447Q33681591-8C50D75A-A850-4301-9937-F0D945B7D7FCQ33819478-02BEBFF2-1561-44D2-B922-4894C3231E29Q33874790-5E187516-B825-4809-93E5-351596B56860Q33879437-B9768410-8F4F-4BBC-A533-F208965478B7Q34035727-73CA66B6-3B84-40AE-9B29-77C9E72B37BFQ34073191-7088EA0E-FF32-4A8C-AFA6-7BA4F856C760Q34078707-227D63B0-D5D6-48A4-B010-1FD67685819AQ34147687-B8F39F8A-79EC-41F2-AE50-E0B4B395C5ACQ34235370-25B397FB-2FC1-4068-8993-D9087E6302E5Q34389885-1A8D897D-2E8A-4CA9-8798-4016B2143C54Q35193565-22AA5435-8264-47A0-A945-6D00C913AEAAQ35207745-B2493C2F-67C7-4CE4-AE16-B791804E1601Q35213972-B72E8840-EB7C-4AC6-BC1B-35028C76503DQ35304737-7900EC16-C0D2-4AF1-8106-3C58BEB7B352Q35557970-9EC617CC-FB23-4CFA-89C3-25C9AB765C61Q35561386-D144B5D9-1EC4-4FBB-BD57-31B5E5EB8606Q35640448-AF90B0F3-6E93-443B-A099-8D8A2F6F810DQ35679414-21EDD1AF-5823-49E2-9ECF-624BEF82845DQ35763489-DE1719F9-91E9-40E5-81FD-068CF5E18980Q36049668-C4CCBC97-74EA-43EF-B8E8-64005DE92F7DQ36578893-EE63FC92-85B9-4367-9095-BEB4B9F1AFA6Q37223169-FADBEBB7-576D-46D1-8C5C-F0DD19A06F62Q37276970-B44B07AD-CC80-47B9-A30A-949D96B9AA18Q37279989-AEDAB006-9E3D-4EC5-A7C3-C2651812A8CDQ37367325-F61E76B0-702F-4414-9154-4B311B2AB006
P2860
Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Withdrawal of immunosuppressio ...... intenance: a randomized trial.
@en
Withdrawal of immunosuppressio ...... intenance: a randomized trial.
@nl
type
label
Withdrawal of immunosuppressio ...... intenance: a randomized trial.
@en
Withdrawal of immunosuppressio ...... intenance: a randomized trial.
@nl
prefLabel
Withdrawal of immunosuppressio ...... intenance: a randomized trial.
@en
Withdrawal of immunosuppressio ...... intenance: a randomized trial.
@nl
P2093
P50
P1433
P1476
Withdrawal of immunosuppressio ...... intenance: a randomized trial.
@en
P2093
Charlotte Magdelaine-Beuzelin
David Ternant
Filip Baert
Geert D'Haens
Gilles Paintaud
Hervé Watier
Maja Noman
P304
P356
10.1053/J.GASTRO.2008.03.004
P407
P577
2008-03-08T00:00:00Z